Skip Navigation Links  

A New Study for People with Mild to Moderate Alzheimer's Disease

Ongoing Study; Not Open for Enrollment

NOBLE is a clinical study to evaluate an investigational drug for patients with mild to moderate Alzheimer's disease. Participants will receive the study drug or a placebo. During this study, if you are already taking medication for Alzheimer’s disease, you will probably continue to take it along with the study drug or placebo. The investigational drug may work by protecting brain cells which could result in improved memory. But, this has not been proven yet. We are doing this study to find out if this is true.

The study will enroll 450 patients with mild to moderate Alzheimer’s disease at many research sites across the United States. Total participation time is about 14 months, which includes screening, about one year of study treatment, and follow up to check safety.

You will be screened to see if you are eligible to participate. Screening includes tests like EKG, blood and urine exams, physical examination, and cognitive testing. Upon enrollment in the study, you will have a 1/3 chance of receiving the low dose of study drug, the high dose of study drug or placebo. Study participants will be seen by researchers every 4 weeks for the first 3 months, then every 6 to 8 weeks for the next 9 months, with a follow up visit 4 weeks later. Cognitive and physical evaluations and blood testing will be conducted at each visit. An MRI scan of the brain will be done at the beginning and end of the study.

Regularly scheduled physician visits are not disrupted by the study. Primary care physicians will be kept informed of your progress and laboratory results. You will also receive regular health assessments by health care professionals who specialize in Alzheimer’s disease.

Your participation is critical for developing effective treatments. People who have Alzheimer's disease are urgently needed to aid researchers in finding new approaches

Selected eligibility criteria:
  • Women and men aged 55-85 years old with mild to moderate Alzheimer's Disease
  • Receiving donepezil (Aricept®) or rivastigmine (Exelon® Patch) treatment for at least six months
  • Living in the community (not nursing homes)
  • Have a study partner that has regular contact with you about 10 hours per week and who will come to study visits with you
  • Weight of no more than 220 pounds

This study is sponsored by Toyama Chemical Co., Ltd and is being conducted by the Alzheimer's Disease Cooperative Study (ADCS).

The NOBLE Study Locations
AZPhoenixBanner Alzheimer's InstituteDawn Batchuluun(602)
AZSun CityBanner Sun Health Research InstituteSherye Sirrel(623)
AZTucsonArizona Health Sciences CenterDerek Gin(520)
CAFullertonNeurology Center of North Orange CountySheraz Mossa(714)879-7200 ext
CALa JollaUniversity of California, San DiegoVictoria Shokrollah(858)
CAOrangeUniversity of California, Irvine - Neuropsychiatric CenterFarah Toullier(714)
CTHamdenGeriatric and Adult PsychiatryAndrea DeClement(203)
CTNew HavenYale University School of MedicineJulia McDonald(203)
CTNorwalkResearch Center for Clinical Research, Inc.Kinjalben Patel(203)
DCWashingtonGeorgetown UniversityMaysa Jawdat(202)
FLHollywoodInfinity Clinical Research, LLCJorge Riveros(954)
FLMiamiUniversity of MiamiCarmen Perez(305)
FLMiami BeachWien Center for Clinical ResearchRosemarie Rodriguez(305)674-2121 ext
FLOcalaRenstar Medical ResearchLinda Mazur(352)
GAAtlantaNeuroTrials Research, Inc.Sandra Beyer(404)
IAIowa CityUniversity of IowaKaren Smith(319)
ILChicagoRush University Medical CenterDavid Sedillo(312)
ILSpringfieldSouthern Illinois UniversityBarbara Lokaitis(217)
INElkhartIndiana Medical Research, LLCKay Stanley(574)
INIndianapolisIndiana UniversityLauren Perrey(317)
KSFairwayUniversity of KansasAnnette Becker(913)
KYLexingtonUniversity of KentuckyPaul Stringer(859)
LABaton RougePennington Biomedical Research CenterErin LeJeune(225)
MABostonBoston UniversityJane Mwicigi(617)
MEBangorAcadia Hospital and Eastern Maine Medical CenterClaudine Allen(207)
MIAnn ArborUniversity of Michigan, Ann ArborJamie Guyot (Miller)(734)
MIAnn ArborUniversity of Michigan, Ann ArborKathryn Steen(734)
MIEast LansingMichigan State UniversityMonica Gruber(517)
MIKalamazooBronson Lakeview HospitalGail Massey(269)
NCWinston-SalemWake Forest University Health SciencesMaria Edelhauser(336)
NEOmahaUniversity of Nebraska Medical CenterRenee Hogue(402)
NJPrincetonPrinceton Medical InstituteKarleen Shim-Chim(609)921-3555 ext
NVLas VegasCleveland Clinic Lou Ruvo Center for Brain HealthYolande Mucharbach(702)
NYAmherstDent Neurologic InstituteCaroline Kumm(716)
NYNew YorkColumbia UniversityRuth Tejeda(212)
NYNew YorkMount Sinai School of MedicineFlorence Lau(212)
NYOrangeburgNathan Kline Institute for Psychiatric ResearchRaymundo Hernando(845)
NYRochesterUniversity of Rochester Medical CenterSusan Salem-Spencer(585)
NYSyracuseSUNY Upstate Medical UniversityCourtney Goodrich(315)
OHBeachwoodCase Western Reserve UniversitySusie Sami(216)
OKTulsaTulsa Clinical ResearchChristy Lisenbee(918)
PAPhiladelphiaUniversity of PennsylvaniaMartha Combs(215)
PAPittsburghUniversity of PittsburghThomas Baumgartner(412)
PAWillow GroveAbington Neurological AssociatesPriscilla Wong(215)957-9250 ext
SCCharlestonRoper St. Francis HospitalRic Freeman(843)
TNNashvilleVanderbilt Memory & Alzheimer’s CenterRenée Martin-Willett(615)
TXForth WorthUniversity of North Texas Health Science CenterKimberly Brown(817)
TXHoustonHouston Methodist Neurological InstituteJennifer Garrett(713)
WIMadisonUniversity of WisconsinMatthew Gilles(608)
WIWaukeshaIndependent Psychiatric ConsultantAnne Dobratz(262)